Notes
The study was funded by Novo Nordisk Inc.
Reference
Li Q, et al. Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States. Diabetes Therapy 5: 579-590, No. 2, Dec 2014. Available from: URL: http://doi.org/10.1007/s13300-014-0084-9
Rights and permissions
About this article
Cite this article
Liraglutide provides better glycaemic control at no extra cost. PharmacoEcon Outcomes News 720, 22 (2015). https://doi.org/10.1007/s40274-015-1861-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-1861-z